Acciones ImmunoPrecise Antibodies Ltd. Toronto S.E.
Acciones
IPA
CA45257F2008
Farmacéuticos
Ventas 2024 * | 24,59 M 17,97 M 16,82 M | Ventas 2025 * | 29,82 M 21,8 M 20,4 M | Capitalización | 47,55 M 34,76 M 32,53 M |
---|---|---|---|---|---|
Resultado Neto 2024 * | -12 M -8,77 M -8,21 M | Resultado Neto 2025 * | -9 M -6,58 M -6,16 M | VE / Ventas 2024 * | 1,93 x |
Posición de caja neta 2024 * | - 0 0 | Posición de caja neta 2025 * | - 0 0 | VE / Ventas 2025 * | 1,59 x |
P/E ratio 2024 * |
-3,76
x | P/E ratio 2025 * |
-5,1
x | Empleados | 102 |
Rendimiento 2024 * |
-
| Rendimiento 2025 * |
-
| Flotante | 86,41 % |
Último transcript sobre ImmunoPrecise Antibodies Ltd.
Directores | Puesto | Edad | Desde |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 21/02/18 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 29/09/23 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/21 |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 05/09/23 |
Jennifer Bath
CEO | Chief Executive Officer | - | 21/02/18 |
Varia. 1 de ene. | Capi. | |
---|---|---|
-4,66 % | 86,13 mil M | |
+1,32 % | 39,82 mil M | |
-19,27 % | 30,42 mil M | |
+57,86 % | 25,23 mil M | |
-17,69 % | 11,6 mil M | |
-43,00 % | 11,51 mil M | |
-9,14 % | 11,95 mil M | |
+5,24 % | 8710,47 M | |
-8,42 % | 8115,21 M |